Fade Mahmoud

2.1k total citations
51 papers, 1.5k citations indexed

About

Fade Mahmoud is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Fade Mahmoud has authored 51 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 13 papers in Molecular Biology and 10 papers in Immunology. Recurrent topics in Fade Mahmoud's work include Cancer Immunotherapy and Biomarkers (14 papers), Melanoma and MAPK Pathways (6 papers) and Immunotherapy and Immune Responses (6 papers). Fade Mahmoud is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Melanoma and MAPK Pathways (6 papers) and Immunotherapy and Immune Responses (6 papers). Fade Mahmoud collaborates with scholars based in United States, United Kingdom and Egypt. Fade Mahmoud's co-authors include Nilo Rivera, Declan Walsh, Kristine A. Nelson, Laura F. Hutchins, Nabeel Sarhill, Madappa N. Kundranda, Rahul Ravilla, Jiaxin Niu, Mellar P. Davis and Tomislav Dragovich and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Fade Mahmoud

48 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fade Mahmoud United States 20 701 403 306 226 193 51 1.5k
Qin Xu China 21 335 0.5× 317 0.8× 263 0.9× 202 0.9× 147 0.8× 98 1.5k
Paola Altieri Italy 28 365 0.5× 594 1.5× 269 0.9× 212 0.9× 208 1.1× 77 2.3k
John C. Michalak United States 19 1.0k 1.5× 278 0.7× 319 1.0× 126 0.6× 367 1.9× 24 1.9k
Dimitrios C. Ziogas Greece 26 913 1.3× 755 1.9× 188 0.6× 301 1.3× 217 1.1× 99 2.2k
Michelle Harrison Australia 23 621 0.9× 255 0.6× 198 0.6× 115 0.5× 233 1.2× 88 1.4k
Wataru Yamamoto Japan 20 355 0.5× 230 0.6× 225 0.7× 193 0.9× 160 0.8× 119 1.6k
Claudio Favre Italy 27 409 0.6× 490 1.2× 90 0.3× 303 1.3× 155 0.8× 94 2.0k
Uyen Huynh‐Do Switzerland 26 252 0.4× 983 2.4× 179 0.6× 232 1.0× 246 1.3× 111 2.7k
Zbigniew Gaciong Poland 19 307 0.4× 831 2.1× 158 0.5× 125 0.6× 229 1.2× 108 1.9k
Shunsaku Nakagawa Japan 18 268 0.4× 304 0.8× 106 0.3× 132 0.6× 161 0.8× 82 1.3k

Countries citing papers authored by Fade Mahmoud

Since Specialization
Citations

This map shows the geographic impact of Fade Mahmoud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fade Mahmoud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fade Mahmoud more than expected).

Fields of papers citing papers by Fade Mahmoud

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fade Mahmoud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fade Mahmoud. The network helps show where Fade Mahmoud may publish in the future.

Co-authorship network of co-authors of Fade Mahmoud

This figure shows the co-authorship network connecting the top 25 collaborators of Fade Mahmoud. A scholar is included among the top collaborators of Fade Mahmoud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fade Mahmoud. Fade Mahmoud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mahmoud, Fade, et al.. (2025). Talimogene laherparepvec induced bullous pemphigoid. JAAD Case Reports. 60. 115–117.
2.
Kundranda, Madappa N., et al.. (2021). Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors. Current Oncology Reports. 23(9). 100–100. 37 indexed citations
3.
Ravilla, Rahul, et al.. (2020). Immunotherapy Outcomes in Advanced Melanoma in Relation to Age. The Permanente Journal. 24(2). 10 indexed citations
4.
Koss, Brian, Erin M. Taylor, Aaron J. Storey, et al.. (2019). Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. Cancer Research. 79(6). 1113–1123. 42 indexed citations
5.
Kundranda, Madappa N., Jiaxin Niu, Boris G. Naraev, et al.. (2018). Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. OncoTargets and Therapy. Volume 11. 7095–7107. 191 indexed citations
6.
Niu, Jiaxin, et al.. (2018). Systemic therapy in patients with NSCLC with brain metastasis: the emerging role of immunotherapy. Neuroimmunology and Neuroinflammation. 5(8). 32–32. 3 indexed citations
7.
Ravilla, Rahul, et al.. (2018). Outcomes of immunotherapy in advanced melanoma in relation to age.. Journal of Clinical Oncology. 36(5_suppl). 187–187. 5 indexed citations
8.
Youssef, Alexey, et al.. (2018). Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors. SHILAP Revista de lepidopterología. 2018. 1–4. 30 indexed citations
9.
Mahmoud, Fade, et al.. (2018). Invasive Basal Cell Carcinoma of the Skin Treated Successfully with Vismodegib: A Case Report. The Permanente Journal. 22(3). 17–181. 5 indexed citations
10.
Mahmoud, Fade, Erin M. Taylor, Stephanie D. Byrum, et al.. (2017). Indicators of responsiveness to immune checkpoint inhibitors. Scientific Reports. 7(1). 807–807. 60 indexed citations
11.
Ravilla, Rahul, et al.. (2017). Pembrolizumab-Induced Pancytopenia: A Case Report. The Permanente Journal. 21(3). 17–4. 25 indexed citations
12.
Govindarajan, Rangaswamy, James Posey, Calvin Chao, et al.. (2016). A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancer. BMC Cancer. 16(1). 368–368. 12 indexed citations
13.
Makhoul, Issam, Konstantinos Arnaoutakis, Fade Mahmoud, et al.. (2016). Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program. Journal of Cancer Education. 33(1). 186–192. 1 indexed citations
14.
Davis, Mellar P., et al.. (2011). A Phase II Dose Titration Study of Thalidomide for Cancer-Associated Anorexia. Journal of Pain and Symptom Management. 43(1). 78–86. 27 indexed citations
15.
Mahmoud, Fade & Rajesh R. Tampi. (2011). Valproic Acid–Induced Parkinsonism in the Elderly: A Comprehensive Review of the Literature. ˜The œAmerican journal of geriatric pharmacotherapy. 9(6). 405–412. 44 indexed citations
16.
Lasheen, Wael, Declan Walsh, Fade Mahmoud, et al.. (2009). The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain. Palliative Medicine. 24(1). 9–16. 14 indexed citations
17.
Walsh, Declan, Kristine A. Nelson, & Fade Mahmoud. (2003). Established and potential therapeutic applications of cannabinoids in oncology. Supportive Care in Cancer. 11(3). 137–143. 126 indexed citations
18.
Walsh, Declan, Fade Mahmoud, & Barbara P. Barna. (2003). Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Supportive Care in Cancer. 11(1). 60–62. 66 indexed citations
19.
Sarhill, Nabeel, Fade Mahmoud, Declan Walsh, et al.. (2003). Evaluation of nutritional status in advanced metastatic cancer. Supportive Care in Cancer. 11(10). 652–659. 119 indexed citations
20.
Mahmoud, Fade & Nilo Rivera. (2002). The role of C-reactive protein as a prognostic indicator in advanced cancer. Current Oncology Reports. 4(3). 250–255. 253 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qin Xu Breakdown of academic impact, for papers by Paola Altieri Breakdown of academic impact, for papers by John C. Michalak Breakdown of academic impact, for papers by Dimitrios C. Ziogas Breakdown of academic impact, for papers by Michelle Harrison Breakdown of academic impact, for papers by Wataru Yamamoto Breakdown of academic impact, for papers by Claudio Favre Breakdown of academic impact, for papers by Uyen Huynh‐Do Breakdown of academic impact, for papers by Zbigniew Gaciong Breakdown of academic impact, for papers by Shunsaku Nakagawa
Rankless by CCL
2026